Patents by Inventor Michael Matzke

Michael Matzke has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Arylsulphonamides and analogues
    Patent number: 6727279
    Abstract: The present invention relates to novel arylsulphonamides and analogues, to processes for their preparation and to their use for the prophylaxis and treatment of neurodegenerative disorders, in particular for the treatment of cerebral apoplexy, craniocerebral trauma, pain and spasticity.
    Type: Grant
    Filed: August 21, 2002
    Date of Patent: April 27, 2004
    Assignee: Bayer Aktiengesellschaft
    Inventors: Joachim Mittendorf, Jürgen Dressel, Michael Matzke, Jörg Keldenich, Frank Mauler, Jean-Marie-Victor de Vry, Jürgen Franz, Peter Spreyer, Verena Vöhringer, Joachim Schumacher, Michael-Harold Rock, Ervin Horvàth, Arno Friedl, Klaus-Helmut Mohrs, Siegfried Raddatz, Reinhard Jork
  • Aryl sulfonamides and analogues thereof and their use in the treatment of neurodegenerative diseases
    Patent number: 6573278
    Abstract: The present invention relates to new aryl ether sulphonamides and analogues, processes for their preparation and their use for the treatment of neurodegenerative disorders, in particular for the prophylaxis and treatment of neurodegenerative disorders, in particular for the treatment of cerebral apoplexy and craniocerebral trauma.
    Type: Grant
    Filed: June 11, 2001
    Date of Patent: June 3, 2003
    Assignee: Bayer Aktiengesellschaft
    Inventors: Joachim Mittendorf, Jürgen Dressel, Michael Matzke, Jörg Keldenich, Klaus-Helmut Mohrs, Siegfried Raddatz, Jürgen Franz, Peter Spreyer, Verena Vöhringer, Joachim Schuhmacher, Michael-Harold Rock, Ervin Horváth, Arno Friedl, Frank Mauler, Jean Marie Viktor de Vry, Reinhard Jork
  • Novel arylsulphonamides and analogues
    Publication number: 20030073727
    Abstract: The present invention relates to novel arylsulphonamides and analogues, to processes for their preparation and to their use for the prophylaxis and treatment of neurodegenerative disorders, in particular for the treatment of cerebral apoplexy, craniocerebral trauma, pain and spasticity.
    Type: Application
    Filed: August 21, 2002
    Publication date: April 17, 2003
    Inventors: Joachim Mittendorf, Jurgen Dressel, Michael Matzke, Jorg Keldenich, Frank Mauler, Jean-Marie-Victor de Vry, Jurgen Franz, Peter Spreyer, Verena Vohringer, Joachim Schumacher, Michael-Harold Rock, Ervin Horvath, Arno Friedl, Klaus-Helmut Mohrs, Siegfried Raddatz, Reinhard Jork
  • Aryl sulphonamide amino acid esters and analogues
    Patent number: 6545050
    Abstract: The present invention relates to novel amino acid esters of arylsulphonamides and analogues, to processes for their preparation and to their use for the prophylaxis and treatment of neurodegenerative disorders, in particular for the treatment of cerebral apoplexy, craniocerebral trauma, pain and spasticity.
    Type: Grant
    Filed: February 16, 2001
    Date of Patent: April 8, 2003
    Assignee: Bayer Aktiengesellschaft
    Inventors: Joachim Mittendorf, Jürgen Dressel, Michael Matzke, Jörg Keldenich, Frank Mauler, Jean-Marie-Viktor de Vry, Jürgen Franz, Peter Spreyer, Verena Vöhringer, Joachim Schumacher, Michael-Harold Rock, Ervin Horvàth, Arno Friedl
  • Use of known agonists of the central cannabinoid receptor CB1
    Patent number: 6525087
    Abstract: The present invention relates to the use of known agonists of the central cannabinoid receptor CB1 for the prophylaxis and treatment of neurodegenerative disorders, in particular for the treatment of cerebral apoplexy and craniocerebral trauma.
    Type: Grant
    Filed: May 29, 2001
    Date of Patent: February 25, 2003
    Assignee: Bayer Aktiengesellschaft
    Inventors: Joachim Mittendorf, Jürgen Dressel, Michael Matzke, Jürgen Franz, Peter Spreyer, Verena Vöhringer, Joachim Schumacher, Arno Friedl, Ervin Horvath, Frank Mauler, Jean-Marie-Viktor De Vry, Reinhard Jork
  • Aryl sulphonamides and analogues
    Patent number: 6469054
    Abstract: The present invention relates to novel arylsulphonamides and analogues, to processes for their preparation and to their use for the prophylaxis and treatment of neurodegenerative disorders, in particular for the treatment of cerebral apoplexy, craniocerebral trauma, pain and spasticity.
    Type: Grant
    Filed: February 16, 2001
    Date of Patent: October 22, 2002
    Assignee: Bayer Aktiengesellshaft
    Inventors: Joachim Mittendorf, Jürgen Dressel, Michael Matzke, Jörg Keldenich, Frank Mauler, Jean-Marie-Victor de Vry, Jürgen Franz, Peter Spreyer, Verena Vöhringer, Joachim Schumacher, Michael-Harold Rock, Ervin Horvàth, Arno Friedl, Klaus-Helmut Mohrs, Siegfried Raddatz, Reinhard Jork
  • Method for preparing 1-alkyl-pyrazol-5-carboxylic acid esters III
    Patent number: 6444828
    Abstract: 1-Alkyl-pyrazole-5-carboxylic esters are obtained with surprisingly low proportions of 1-alkyl-pyrazole-3-carboxylic esters if a 2,4-diketo ester and/or an enolate thereof is reacted with an alkylhydrazine and/or a corresponding alkylhydrazinium salt, if appropriate, in the presence of a solvent and/or of water, in such a manner that during at least about 90% of the reaction free alkylhydrazine is present.
    Type: Grant
    Filed: February 9, 2001
    Date of Patent: September 3, 2002
    Assignee: Bayer Aktiengesellschaft
    Inventors: Nikolaus Müller, Michael Matzke
  • USE OF 7-(2-OXA-5,8-DIAZABICYLCO[4.3.0]NON-8-YL)-QUINOLONE CARBOXYLIC ACID AND NAPHTHYRIDON CARBOXYLIC ACID DERIVATIVES FOR THE TREATMENT OF HELIOBACTER PYLORI INFECTIONS AND ASSOCIATED GASTRODUODENAL DISEASES
    Patent number: 6432948
    Abstract: The invention relates to the use of quinolone- and naphthyridonecarboxylic acid derivatives, which are substituted in the 7-position by a 2-oxa-5,8-diazabicyclo[4.3.0]-non-8-yl) radical, and their pharmaceutically utilizable hydrates and/or salts for the therapy of Helicobacter pylori infections and the gastroduodenal disorders associated therewith.
    Type: Grant
    Filed: November 8, 1999
    Date of Patent: August 13, 2002
    Assignee: Bayer Aktiengesellschaft
    Inventors: Michael Matzke, Uwe Petersen, Thomas Jaetsch, Stephan Bartel, Thomas Schénke, Thomas Himmler, Bernd Baasner, Hans-Otto Werling, Klaus Schaller, Harald Labischinski
  • Arylsulfonamides and analogues
    Publication number: 20020072529
    Abstract: The present invention relates to new aryl ether sulphonamides and analogues, processes for their preparation and their use for the treatment of neurodegenerative disorders, in particular for the prophylaxis and treatment of neurodegenerative disorders, in particular for the treatment of cerebral apoplexy and craniocerebral trauma.
    Type: Application
    Filed: June 11, 2001
    Publication date: June 13, 2002
    Inventors: Joachim Mittendorf, Jurgen Dressel, Michael Matzke, Jorg Keldenich, Klaus-Helmut Mohrs, Siegfried Raddatz, Jurgen Franz, Peter Spreyer, Verena Vohringer, Joachim Schuhmacher, Michael-Harold Rock, Ervin Horvath, Arno Friedl, Frank Mauler, Jean Marie Viktor de Vry, Reinhard Jork
  • Use of 7-(1-aminomethyl-2-oxa-7-aza-bicyclo[3.3.0]oct-7-yl)-quinolonecarboxylic acid and -naphthyridonecarboxylic acid derivatives for the therapy of Helicobacter pylori infections and associated gastroduodenal disorders
    Publication number: 20010036941
    Abstract: The invention relates to the use of quinolone- and naphthyridonecarboxylic acid derivatives which are substituted in position 7 by a 1-aninomethyl-2-oxa-7-azabicyclo[3.3.0]oct-7-yl radical, and of their salts for the therapy of Helicobacter pylori infections and associated gastroduodenal disorders.
    Type: Application
    Filed: April 10, 2001
    Publication date: November 1, 2001
    Inventors: Uwe Petersen, Michael Matzke, Thomas Jaetsch, Thomas Schenke, Thomas Himmler, Stephan Bartel, Bernd Baasner, Hans-Otto Werling, Klaus Schaller, Harald Labischinski, Rainer Endermann
  • Use of known agonists of the central cannabinoid receptor CB1
    Publication number: 20010034344
    Abstract: The present invention relates to the use of known agonists of the central cannabinoid receptor CB1 for the prophylaxis and treatment of neurodegenerative disorders, in particular for the treatment of cerebral apoplexy and craniocerebral trauma.
    Type: Application
    Filed: May 29, 2001
    Publication date: October 25, 2001
    Inventors: Joachim Mittendorf, Jurgen Dressel, Michael Matzke, Jurgen Franz, Peter Spreyer, Verena Vohringer, Joachim Schuhmacher, Arno Friedl, Ervin Horvath, Frank Mauler, Jean-Marie-Viktor De Vry, Reinhard Jork
  • Method of preparing 1-alkyl-pyrazol-5-carboxylic acid esters
    Patent number: 6297386
    Abstract: The invention relates to the preparation of 1-alkyl-pyrazole-5-carboxylic esters by reacting the enolate of a 2,4-diketocarboxylic ester in the presence of a solvent and water with an N-alkylhydrazinium salt. This process permits a particularly economical preparation of 1-alkyl-pyrazole-5-carboxylic esters in a simple manner and with only limited formation of undesirable isomers.
    Type: Grant
    Filed: January 22, 2001
    Date of Patent: October 2, 2001
    Assignee: Bayer Aktiengesellschaft
    Inventors: Nikolaus Müller, Michael Matzke
  • Use of 7-(1-aminomethyl-2-oxa-7-aza-bicyclo[3.3.0]oct-7-yl)-quinolone carboxylic acid and naphthyridone carboxylic acid derivatives for treating Helicobacter pylori infections and the gastroduodenal diseases associated therewith
    Patent number: 6288081
    Abstract: The invention relates to the use of quinolone- and naphthyridonecarboxylic acid derivatives which are substituted in position 7 by a 1-aminomethyl-2-oxa-7-azabicyclo[3.3.0]oct-7-yl radical, and of their salts for the therapy of Helicobacter pylori infections and associated gastroduodenal disorders.
    Type: Grant
    Filed: August 6, 1999
    Date of Patent: September 11, 2001
    Assignee: Bayer Aktiengesellschaft
    Inventors: Uwe Petersen, Michael Matzke, Thomas Jaetsch, Thomas Schenke, Thomas Himmler, Stephan Bartel, Bernd Baasner, Hans-Otto Werling, Klaus Schaller, Harald Labischinski, Rainer Endermann
  • Use of known agonists of the central cannabinoid receptor CB1
    Patent number: 6284788
    Abstract: The present invention relates to the use of known agonists of the central cannabinoid receptor CB1 for the prophylaxis and treatment of neurodegenerative disorders, in particular for the treatment of cerebral apoplexy and craniocerebral trauma.
    Type: Grant
    Filed: February 17, 1998
    Date of Patent: September 4, 2001
    Assignee: Bayer Aktiengesellschaft
    Inventors: Joachim Mittendorf, Jürgen Dressel, Michael Matzke, Jürgen Franz, Peter Spreyer, Verena Vöhringer, Joachim Schuhmacher, Arno Friedl, Ervin Horvath, Frank Mauler, Jean-Marie-Viktor De Vry, Reinhard Jork
  • Aryl sulfonamides and analogues thereof and their use in the treatment of neurodegenerative diseases
    Patent number: 6262112
    Abstract: The present invention relates to new aryl ether sulphonamides and analogs, processes for their preparation and their use for the treatment of neurodegenerative disorders, in particular for the prophylaxis and treatment of neurodegenerative disorders, in particular for the treatment of cerebral apoplexy and craniocerebral trauma.
    Type: Grant
    Filed: November 15, 1999
    Date of Patent: July 17, 2001
    Assignee: Bayer Aktiengesellschaft
    Inventors: Joachim Mittendorf, Jürgen Dressel, Michael Matzke, Jörg Keldenich, Klaus-Helmut Mohrs, Siegfried Raddatz, Jürgen Franz, Peter Spreyer, Verena Vöhringer, Joachim Schuhmacher, Michael-Harold Rock, Ervin Horváth, Arno Friedl, Frank Mauler, Jean Marie Viktor de Vry, Reinhard Jork
  • Use of 7-(2-oxa-5,8-diazabicyclo[4.3.0]non-8-yl)-quinolone carboxylic acid and naphthyridon carboxylic acid derivatives for the treatment of Helicobacter pylori infections and associated gastroduodenal diseases
    Patent number: 6133260
    Abstract: The invention relates to the use of quinolone- and naphthyridonecarboxylic acid derivatives which are substituted in the 7-position by a 2-oxa-5,8-diazabicyclo[4.3.0]-non-8-yl) radical, and their pharmaceutically utilizable hydrates and/or salts for the therapy of Helicobacter pylori infections and the gastroduodenal disorders associated therewith.
    Type: Grant
    Filed: June 14, 1999
    Date of Patent: October 17, 2000
    Assignee: Bayer Aktiengesellschaft
    Inventors: Michael Matzke, Uwe Petersen, Thomas Jaetsch, Stephan Bartel, Thomas Schenke, Thomas Himmler, Bernd Baasner, Hans-Otto Werling, Klaus Schaller, Harald Labischinski
  • High enantio-selective process for producing pure enantiomeric cyclopentane and cyclopentene-(.beta.)-amino acids
    Patent number: 5962724
    Abstract: The present invention relates to a highly enantioselective process for the preparation of enantiomerically pure cyclopentane- and -pentene .beta.-amino acids of the general formula (I) ##STR1## in which A and L, A and D or E and L, D and E, R.sup.2, R.sup.3, T and R.sup.1 have the meaning given in the description.
    Type: Grant
    Filed: July 5, 1996
    Date of Patent: October 5, 1999
    Assignee: Bayer Aktiengesellschaft
    Inventors: Joachim Mittendorf, Hermann Arold, Peter Fey, Michael Matzke, Hans-Christian Militzer, Klaus-Helmut Mohrs
  • Tolerability of pharmaceutically active .beta.-amino acids
    Patent number: 5935988
    Abstract: The present invention relates to mixtures of .alpha.-amino acids and/or derivatives thereof and cyclopentane-.beta.-amino acids and/or derivatives thereof, dipeptides of the abovementioned .alpha.-amino acids and cyclopentane-.beta.-amino acids and mixtures of the abovementioned mixtures and dipeptides which have an improved tolerability in warm-blooded animals compared with the pure cyclopentane-.beta.-amino acids.
    Type: Grant
    Filed: July 12, 1996
    Date of Patent: August 10, 1999
    Assignee: Bayer Aktiengesellschaft
    Inventors: Michael Matzke, Hans-Christian Militzer, Joachim Mittendorf, Franz Kunisch, Axel Schmidt, Wolfgang Schonfeld, Karl Ziegelbauer
  • Heterocyclically substituted phenylacetic acid derivatives and their use in medicaments
    Patent number: 5776964
    Abstract: The invention relates to phenylacetic acid derivatives which are substituted by a five-membered nitrogen heterocycle bonded via an N atom. They are prepared by reaction of phenylacetic acid derivatives substituted with leaving groups with the appropriate nitrogen heterocycles and can be used as active substances in medicaments for the treatment of high blood pressure and atherosclerosis.
    Type: Grant
    Filed: March 1, 1996
    Date of Patent: July 7, 1998
    Assignee: Bayer Aktiengesellschaft
    Inventors: Ulrich Muller, Klaus Mohrs, Jurgen Dressel, Rudolf Hanko, Walter Hubsch, Michael Matzke, Ulrich Niewohner, Siegfried Raddatz, Thomas Kramer, Matthias Muller-Gliemann, Hans-Peter Bellemann, Martin Beuck, Stanislav Kazda, Stefan Wohlfeil
  • Method of preserving materials using 4-methylene-2-amino-cyclopentane-1-carboxylic acids
    Patent number: 5770622
    Abstract: The invention relates to cyclopentane- and -pentene-.beta.-amino acids, processes for their preparation and their use as medicaments, and to prevent contamination of materials such as wood and leather.
    Type: Grant
    Filed: September 6, 1996
    Date of Patent: June 23, 1998
    Assignee: Bayer Aktiengesellschaft
    Inventors: Joachim Mittendorf, Franz Kunisch, Michael Matzke, Hans-Christian Militzer, Rainer Endermann, Karl Georg Metzger, Klaus-Dieter Bremm, Manfred Plempel